Amarin Corp Plcuk (AMRN) Operating Leases (2019 - 2026)
Amarin Corp Plcuk (AMRN) reported Operating Leases of $7.7 million for Q1 2026, down 25.24% year-over-year from $10.3 million in Q1 2025, and down 6.1% quarter-over-quarter from $8.2 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Operating Leases (2019 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 8 years of Operating Leases data on file, last reported at $7.7 million in Q1 2026.
- Operating Leases for Q1 2026 came in at $7.7 million, down 25.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.7 million (down 25.24% YoY), and the FY2025 annual result was $8.2 million, up 6.18% from the prior year.
- Operating Leases slipped to $7.7 million in Q1 2026 per AMRN's latest filing, from $8.2 million in the prior quarter.
- Over five years, Operating Leases peaked at $11.7 million in Q1 2023 and troughed at $6.7 million in Q3 2025.
- A 5-year average of $9.5 million and a median of $9.7 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2025: Operating Leases climbed 25.35% in 2022, then slumped 34.01% in 2025.
- A 5-year view of Operating Leases shows it stood at $10.0 million in 2022, then climbed by 5.84% to $10.6 million in 2023, then declined by 27.14% to $7.7 million in 2024, then gained by 6.18% to $8.2 million in 2025, then fell by 6.1% to $7.7 million in 2026.
- Business Quant data shows AMRN's Operating Leases at $7.7 million in Q1 2026, $8.2 million in Q4 2025, and $6.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.70 Mn |
| Dec 31, 2025 | 8.20 Mn |
| Sep 30, 2025 | 6.73 Mn |
| Jun 30, 2025 | 9.60 Mn |
| Mar 31, 2025 | 10.30 Mn |
| Dec 31, 2024 | 7.72 Mn |
| Sep 30, 2024 | 10.20 Mn |
| Jun 30, 2024 | 9.70 Mn |
| Mar 31, 2024 | 8.39 Mn |
| Dec 31, 2023 | 10.60 Mn |
| Sep 30, 2023 | 8.97 Mn |
| Jun 30, 2023 | 9.47 Mn |
| Mar 31, 2023 | 11.70 Mn |
| Dec 31, 2022 | 10.02 Mn |
| Sep 30, 2022 | 11.00 Mn |
| Jun 30, 2022 | 10.17 Mn |
| Mar 31, 2022 | 11.30 Mn |
| Dec 31, 2021 | 8.58 Mn |
| Sep 30, 2021 | 10.50 Mn |
| Jun 30, 2021 | 10.50 Mn |